Case Study: Ensysce Biosciences achieves faster modified release formulation development with Quotient Sciences' Translational Pharmaceutics

Ensysce Biosciences reaches successful modified release formulation in 12 months with Quotient Sciences

Ensysce Biosciences, a clinical-stage biotech company, faced a significant challenge in developing a modified release formulation for its leading pain treatment product, PF614-MPAR. After speaking with a traditional contract organization, CEO Dr. Lynn Kirkpatrick realized it could take years to arrive at a successful formulation. They approached Quotient Sciences to overcome this challenge.

Quotient Sciences implemented its integrated Translational Pharmaceutics platform, which combined formulation development, real-time clinical manufacturing, and clinical dosing under a single organization. This approach provided the flexibility to test multiple prototypes under a single clinical protocol. As a result, Quotient Sciences helped Ensysce Biosciences achieve a successful modified release formulation in an accelerated time frame of just twelve months, drastically cutting down the anticipated development timeline.

Ensysce Biosciences